Personalis-Tempus AI deal clears US antitrust waiting period under HSR Act

Bitget2026/10/06 20:07

Tempus AI agreed to acquire Personalis through a two-step merger, leaving Personalis as an indirect wholly owned Tempus unit. The antitrust waiting period for the deal expired at 11:59 p.m. ET on Oct. 2, 2026. Tempus withdrew its initial filing on Aug. 31, 2026, then refiled on Sept. 2, 2026, restarting the 30-day clock. Closing now hinges on Personalis shareholder approval at a virtual meeting, with the date still to be set. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Personalis Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-415547), on October 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Citi: French fiscal risks may cause ECB to pause rate hikes after December, euro likely to drop below 1.10

华尔街见闻•2026/10/10 07:43

Morgan Stanley raises CME Group price target to $337

格隆汇•2026/10/10 07:37

Chip design software leader Synopsys seeks collaboration with Chinese large model laboratories

Chaincatcher•2026/10/10 07:19

Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials

Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.

智通财经•2026/10/10 06:21